Overactive bladder, also called OAB, causes a frequent and sudden urge to urinate that may be difficult to control. Overactive bladder occurs as muscles of the bladder start to contract involuntarily even when the volume of urine in bladder is low. These involuntary contractions create an urgent need to urinate. One may feel the need to pass urine many times during day and night, and may also experience unintentional loss of urine (urgency incontinence). The symptoms include, feeling of a sudden urge to urinate, which is difficult to control; experience unintentional loss of urine immediately after an urgent need to urinate (urgency incontinence); urinate frequently, usually eight or more times in 24 hours; and wake up more than two times in the night to urinate (nocturia).

Market scope and structure analysis:

COVID-19 scenario analysis: 

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing  to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The major factor affecting the industry includes increase in prevalence of urinary incontinence among women and geriatric population. Furthermore, increase in number of product launches and approvals for generics is expected to propel the market growth. Various key companies are focused on availing strategic alliances such that they get to expand in several regions, which are more susceptible to boost the industry. 

Growth in the number of product launches to boost the market

Growth in number of product launches is expected to help the industry flourish during the forecast period. For instance, the FDA approved cefiderocol (FETROJA) in patients of 18 years of age or older who have limited or no alternative treatment options, for complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative microorganisms such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.

In December 2019, Urovant Sciences announced that it had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of once-daily 75mg vibegron for treatment of patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Hence such products are anticipated to propel the market growth.

Surge in number of mergers and acquisitions to propel the market

Increase in number of mergers and acquisitions is anticipated to help the industry boost in the coming years. For instance, in March 2018, Laborie had entered into a $239 million deal to buy Cogentix Medical. The takeover will give Laborie control of devices for treatment of overactive bladder (OAB) and stress urinary incontinence (SUI). Cogentix built its business around a urology portfolio spearheaded by a neuromodulation device to treat overactive bladder and a soft-tissue bulking agent for managing stress urinary incontinence. 

Key segments covered:

Key benefits of the report:

• This study presents the analytical depiction of the global overactive bladder treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global overactive bladder treatment market share.
• The current market is quantitatively analyzed from 2020 to 2027 to highlight the global overactive bladder treatment market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
• The report provides a detailed global overactive bladder treatment market analysis based on competitive intensity and how the competition will take shape in coming years. 

Questions answered in the overactive bladder treatment market research report:

• Which are the leading market players active in the overactive bladder treatment market?
• What would be the detailed impact of COVID-19 on the market?
• What current trends would influence the market in the next few years?
• What are the driving factors, restraints, and opportunities in the overactive bladder treatment market?
• What are the projections for the future that would help in taking further strategic steps?